Results 41 to 50 of about 2,022,996 (246)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Cancer is characterized by an accumulation of somatic mutations, of which a significant subset can generate cancer-specific neoepitopes that are recognized by autologous T cells.
Chuan Wang, Kaïdre Bendjama, Stephen Schoenberger, Oliver Wood, Gareth Thomas, Pandurangan Vijayanand, Tilman Sanchez-Elsner, Nathalie Silvestre, Natalia Savelyeva, Christian Ottensmeier, Katy McCann, Adrian von Witzleben, Jaya Thomas, Divya Singh, Konstantinos Boukas, Finn Cilius Nielsen, Jason Greenbaum, Bjoern Peters   +17 more
doaj   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Characterization of the Neoantigen Profile in a Tumor Mutation Burden-high Melanoma Patient With Multiple Metastases

Cancer Genomics - Proteomics
Recently, neoantigen (NA) profiling has been intensively performed for the development of novel immunotherapy. We previously reported a melanoma case with a high tumor mutation burden that achieved complete remission after anti-programmed death-1 therapy. We herein revisited the same case, characterized the NA profiles of other metastatic lesions using
YOSHIKAWA, SHUSUKE, MAEDA, CHIE, IIZUKA, AKIRA, IKEYA, TOMOATSU, YAMASHITA, KAZUE, ASHIZAWA, TADASHI, KANEMATSU, AKARI, MIYATA, HARUO, KIKUCHI, YASUFUMI, URAKAMI, KENICHI, OHSHIMA, KEIICHI, NAGASHIMA, TAKESHI, YAMAGUCHI, KEN, KIYOHARA, YOSHIO, AKIYAMA, YASUTO   +14 more
openaire   +2 more sources

The Development of Tumor Neoantigen Vaccine Immunotherapy

, 2019
Activating the immune system to fight against cancers has long been a goal in immunology and oncology studies. Recent clinical-trial data proved that boosting the activity of endogenous T cells to destroy cancer cells has great potential in controlling ...
Wanqiu Wang, Wang Wanqiu
core   +1 more source

Engineering Antigen Density on M13 Bacteriophage for Personalized Nanovaccine

Advanced Healthcare Materials, EarlyView.
Increasing antigen density on the phage capsid impacts phage uptake and antigen cross‐presentation by antigen‐presenting cells, leading to enhanced activation of antitumor CD8+ T cells in the draining lymph nodes. These activated CD8+ T cells subsequently recognize the antigen‐expressing tumors and mediate their specific cytotoxic killing, thereby ...
Shengnan Huang, Allison Madow, Jack Rudrum, Huaiyao Peng, Hao Nghi Luu, Peiyan Dong, Jifa Qi, Angela M. Belcher   +7 more
wiley   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes

Nature Communications
Despite the transformative impact of cancer immunotherapy, the need for improved patient stratification remains critical due to suboptimal response rates.
Ko-Han Lee, Timothy J. Sears, Maurizio Zanetti, Hannah Carter   +3 more
doaj   +1 more source

PGNneo: A Proteogenomics-Based Neoantigen Prediction Pipeline in Noncoding Regions

Cells, 2023
The development of a neoantigen-based personalized vaccine has promise in the hunt for cancer immunotherapy. The challenge in neoantigen vaccine design is the need to rapidly and accurately identify, in patients, those neoantigens with vaccine potential.
Xiaoxiu Tan, Linfeng Xu, Xingxing Jian, Jian Ouyang, Bo Hu, Xinrong Yang, Tao Wang, Lu Xie   +7 more
doaj   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Recent advances in neoantigen vaccines for treating non‐small cell lung cancer

Thoracic Cancer, 2023
The breakthrough of programmed cell death protein 1 (PD‐1) blockade therapy has changed the clinical treatment of non‐small cell lung cancer (NSCLC) in the past few years.
Shu Su, Fungjun Chen, Mingyuan Xu, Baorui Liu, Lifeng Wang   +4 more
doaj   +1 more source